Information Provided By: 
Fly News Breaks for May 9, 2017
TXMD
May 9, 2017 | 06:49 EDT
Jefferies analyst Matthew Andrews lowered his price target for TherapeuticsMD to $15 citing a lower probability of success for TX-004HR following the Complete Response Letter. The analyst, with a 55% probability of approval now, believes the FDA's endometrial safety concerns appear addressable. If FDA agrees to approve '004 with a post-approval study, it could obtain a class label with boxed warning, Andrews tells investors in a research note. He keeps a Buy rating on TherapeuticsMD.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
